Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) presented preclinical data for ALPN-303 at the EULAR Congress, highlighting its potential in treating systemic lupus erythematosus and other autoimmune diseases. The data demonstrated that ALPN-303 showed greater efficacy than existing therapies, inhibiting cytokine activity and improving pharmacokinetics. In mouse models, it significantly reduced harmful antibodies and inflammation while preserving kidney function. The company plans to initiate first-in-human studies later this year, reflecting strong interest in its therapeutic approach.
- ALPN-303 demonstrated superior inhibition of BAFF and APRIL compared to wild-type TACI-Fc and existing anti-BAFF therapies.
- Enhanced pharmacokinetics and pharmacodynamics were observed in preclinical studies, including better serum exposure.
- In mouse models, ALPN-303 significantly reduced anti-dsDNA antibody levels and kidney inflammation while preserving renal function.
- None.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today made an oral presentation of preclinical data from the company’s ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting, entitled “ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases.”
Presentation highlights include:
- ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody.
- ALPN-303 exhibited superior preclinical pharmacokinetics and pharmacodynamics than wild-type TACI-Fc counterparts, including superior serum exposure, suppression of T-dependent antibody production, and/or serum immunoglobulins in mice and/or cynomolgus monkeys.
- In a mouse model of lupus, ALPN-303 treatment significantly suppressed anti-double stranded DNA antibody titers, inflammation in the kidneys (glomerulonephritis) and salivary glands (sialadenitis), while preserving renal function and improving survival.
“We’re particularly excited by these findings,” commented Dr. Stanford Peng, Alpine’s President and Head of Research and Development. “There continues to be significant interest in novel therapeutics that target the APRIL and BAFF pathways, and these data suggest that ALPN-303 may be superior for the treatment of severe diseases like lupus. We hope to initiate its first-in-human study later this year.”
This oral presentation is live on the EULAR congress website at https://congress.eular.org/ A copy of the oral presentation slides are available on the Scientific Publications page of Alpine’s website.
About ALPN-303
ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases. Engineered by directed evolution, ALPN-303 potently inhibits the pleiotropic B cell cytokines B cell activating factor (BAFF, BLyS) and a proliferation inducing ligand (APRIL), which play key roles in B cell development, differentiation, and survival, and together contribute to the pathogenesis of multiple autoimmune diseases like systemic lupus erythematosus (SLE), Sjögren’s syndrome, inflammatory arthritis, multiple sclerosis, and many others. By simultaneously blocking these two cytokines, ALPN-303 has the potential to improve outcomes in patients suffering from severe autoimmune and/or inflammatory diseases.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.
“Secreted Immunomodulatory Proteins”, “SIP”, “Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,” “vIgD” and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.
Source: Alpine Immune Sciences Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005925/en/
FAQ
What are the key findings from the ALPN-303 presentation by Alpine Immune Sciences?
When does Alpine Immune Sciences plan to start human trials for ALPN-303?
What autoimmune diseases could ALPN-303 potentially treat?
